Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.
For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
The first ‘real-world study’ into the weight loss drug, Mounjaro, has now started in Greater Manchester. Thousands of ...
StockStory.org on MSN
Why Eli Lilly (LLY) stock is trading up today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the ...
A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...
Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback